Personalis Return on Tangible Equity 2018-2024 | PSNL
Current and historical return on tangible equity values for Personalis (PSNL) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Personalis Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-09-30 |
$-0.09B |
$0.17B |
-69.57% |
| 2024-06-30 |
$-0.08B |
$0.11B |
-63.94% |
| 2024-03-31 |
$-0.09B |
$0.12B |
-64.47% |
| 2023-12-31 |
$-0.11B |
$0.13B |
-67.08% |
| 2023-09-30 |
$-0.11B |
$0.15B |
-61.16% |
| 2023-06-30 |
$-0.11B |
$0.18B |
-53.01% |
| 2023-03-31 |
$-0.11B |
$0.19B |
-49.62% |
| 2022-12-31 |
$-0.11B |
$0.22B |
-44.66% |
| 2022-09-30 |
$-0.10B |
$0.24B |
-36.96% |
| 2022-06-30 |
$-0.09B |
$0.27B |
-31.68% |
| 2022-03-31 |
$-0.08B |
$0.29B |
-25.69% |
| 2021-12-31 |
$-0.07B |
$0.31B |
-19.67% |
| 2021-09-30 |
$-0.06B |
$0.33B |
-19.22% |
| 2021-06-30 |
$-0.05B |
$0.34B |
-18.42% |
| 2021-03-31 |
$-0.04B |
$0.35B |
-20.95% |
| 2020-12-31 |
$-0.04B |
$0.20B |
-27.75% |
| 2020-09-30 |
$-0.04B |
$0.20B |
-27.83% |
| 2020-06-30 |
$-0.03B |
$0.09B |
-31.22% |
| 2020-03-31 |
$-0.03B |
$0.10B |
-26.73% |
| 2019-12-31 |
$-0.03B |
$0.11B |
-31.04% |
| 2019-06-30 |
$-0.02B |
$0.12B |
-54.70% |
| 2019-03-31 |
$-0.02B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.354B |
$0.073B |
|
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|
